Baseline IgE Associated With AD Flares Without Dupilumab
Key Takeaways
- Among adults with moderate-to-severe atopic dermatitis receiving topical corticosteroids without dupilumab, higher baseline IgE was significantly associated with more flares.
- The baseline IgE association with flares was significant in severe AD but not moderate AD.
- Baseline EASI severity was not significantly associated with flares in the reported overall comparison.
- IgE declined significantly on dupilumab, while neither baseline IgE nor baseline severity was significantly associated with flares at week 52 in that group.
Investigators assessed adults older than 18 years in the LIBERTY AD CHRONOS analysis of baseline total IgE and atopic dermatitis flares. Participants received dupilumab 300 mg every 2 weeks or placebo, both with topical corticosteroids (TCS), for 52 weeks. A flare meant disease worsening requiring treatment escalation. Investigators evaluated flare probability in relation to baseline total IgE and baseline severity measured by the Eczema Area and Severity Index (EASI). They also evaluated change in the IgE level ratio over the treatment period. Association estimates were expressed as odds ratios (ORs) and confidence intervals (CIs).
Among participants receiving placebo and TCS, higher baseline total IgE was associated with greater flare probability: OR 1.59 (95% CI 1.18–2.13), P=.002. Baseline AD severity measured with EASI was not significantly associated with flares in the reported overall comparison. Thus, the reported IgE association did not simply mirror the baseline severity finding.
By severity subgroup, the baseline IgE association with flares was significant in severe AD, with OR 1.95 (95% CI 1.33–2.85). The separate estimate in moderate AD was OR 1.02 and was not statistically significant. Among dupilumab-treated participants, IgE decreased significantly during treatment, although a numerical reduction was not reported. Neither baseline total IgE nor baseline EASI severity was significantly associated with flares at week 52 in that group.
The IgE decline during dupilumab treatment and the reported flare findings occurred together. Their coexistence does not establish that lowering IgE caused fewer flares. Likewise, an association between a baseline biomarker and subsequent flares does not show what would happen if the biomarker itself changed. These distinctions limit what the findings can say about a mechanism connecting IgE levels and flare probability.
The authors interpreted elevated total IgE as associated with flares in adults with moderate-to-severe AD beyond what baseline disease severity alone explained. They also reported lower IgE during dupilumab treatment and associated that pattern with reduced flare probability. That interpretation concerns the reported associations, not proof that the IgE decline produced the flare pattern.
Clinician Questions
Is there a baseline total IgE cutoff that predicts atopic dermatitis flares in individual adults?
The association between starting total IgE and subsequent treatment-escalation flares among adults with moderate-to-severe atopic dermatitis receiving topical corticosteroids without dupilumab is a group-level finding. No validated IgE cutoff or measure of individual-level predictive performance is provided.
Was the difference in the IgE–flare association between severe and moderate atopic dermatitis formally tested?
No formal severity-by-IgE interaction statistic is provided. The significant association in severe disease and nonsignificant association in moderate disease therefore do not, by themselves, establish a confirmed difference in association by severity.
Recommended Reading
- For more on dupilumab treatment in AD: Dupilumab Linked to Early Symptom Relief in Atopic Dermatitis